ABSTRACT
The successes of genome sequencing efforts have been widely discussed in the popular and scientific press, including predictions that genetic characterizations of individual risk of disease (and likely responses to therapeutic agents) will soon become routine medical procedures. We have clearly arrived in a new “genomic” era, where our understanding of the mammalian genome and its products is expanding at an increasing rate, and we are challenged to put mountains of data in a true biological context. This impact is being felt in our discipline of toxicology where, over the last decade, large-scale analysis of genes, proteins, and metabolites has become a more integrated, widespread, and mainstream approach in predictive and mechanistic toxicology.
